Trials
Search / Trial NCT05645484

The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma

Launched by WUHAN UNION HOSPITAL, CHINA · Dec 2, 2022

Trial Information

Current as of January 22, 2025

Unknown status

Keywords

ClinConnect Summary

Melanoma is an aggressive malignancy with a high mortality rate. Accurate diagnosis and prognostic risk assessment are essential to the clinical management of melanoma. Melanin is present in most melanoma and has become a potential target for melanoma. This team has successfully synthesized a positron nuclide targeting melanin probe named 18F-PFPN (18F-N-(2-diethylaminoethyl)-4-(2-\[2-ethoxy\]-ethoxy) pyridine), which has been proven to be safe and well-tolerated. It has shown excellent diagnostic value in both primary and metastatic melanoma. This prospective study was designed to further ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with histopathologically confirmed melanoma;
  • Patients with complete clinical and follow-up data (including TNM stage, subtypes, and treatment strategies).
  • Exclusion Criteria:
  • Uncertain histopathology;
  • A history of other malignancies.

Trial Officials

Xiaoli Lan, PhD

Study Director

Wuhan Union Hospital, China

About Wuhan Union Hospital, China

Wuhan Union Hospital, affiliated with Huazhong University of Science and Technology, is a leading medical institution located in Wuhan, China. Renowned for its comprehensive healthcare services and advanced research capabilities, the hospital plays a pivotal role in clinical trials aimed at enhancing medical knowledge and patient care. With a commitment to innovation and excellence, Wuhan Union Hospital collaborates with various stakeholders to conduct rigorous and ethically sound clinical research, contributing significantly to the advancement of medical science and public health both domestically and internationally.

Locations

Wuhan, Hubei, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials